Pirtobrutinib (LOXO‐305), a next generation highly selective non‐covalent BTK inhibitor in previously treated richter transformation: Results from the phase 1/2 bruin study Meeting Abstract
| Authors: | Jurczak, W.; Shah, N. N.; Lamanna, N.; Eyre, T. A.; Woyach, J.; Lech‐Maranda, E.; Wierda, W. G.; Lewis, D.; Thompson, M. C.; Wang, D.; Yin, M.; Balbas, M.; Nair, B. C.; Zhu, E. Y.; Tsai, D. E.; Ku, N. C.; Coombs, C. C.; Mato, A. R. |
| Abstract Title: | Pirtobrutinib (LOXO‐305), a next generation highly selective non‐covalent BTK inhibitor in previously treated richter transformation: Results from the phase 1/2 bruin study |
| Meeting Title: | 16th International Conference on Malignant Lymphoma - Virtual Edition |
| Journal Title: | Hematological Oncology |
| Volume: | 39 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2021 Jun 18-22 |
| Meeting Location: | Virtual |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2021-06-01 |
| Start Page: | 191 |
| End Page: | 192 |
| Language: | English |
| ACCESSION: | 150947478 |
| DOI: | 10.1002/hon.41_2880 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| PUBMED: | 34105791 |
| DOI/URL: | |
| Notes: | Meeting Abstract: 129 -- Accession Number: 150947478 -- Entry Date: In Process -- Revision Date: 20210618 -- Publication Type: Article -- Supplement Title: Jun2021 Supplement S2 -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 8307268. -- Source: Cinahl |
Altmetric
Citation Impact
BMJ Impact Analytics
